Who is on it, and how far along Every drug ChEMBL records acting on TOP2A, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Etoposide Etoposide SponsorGSK ModalitySmall molecule ActionInhibitor Open trials494 Dexrazoxane Dexrazoxane SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials18 Teniposide Teniposide SponsorHQ Specialty Pharma ModalitySmall molecule ActionInhibitor Open trials7 Amsacrine Amsacrine SponsorNot known ModalitySmall molecule ActionInhibitor Open trials2 Phase 33 Vosaroxin Vosaroxin SponsorSunesis Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials1 Becatecarin Becatecarin SponsorHelsinn Healthcare ModalitySmall molecule ActionInhibitor Open trials0 Pazufloxacin Pazufloxacin SponsorLaboratorios Sophia S.A de C.V. ModalitySmall molecule ActionInhibitor Open trials0 Phase 22 Berubicin Berubicin SponsorCNS Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials1 C-1311 C-1311 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: DNA topoisomerase II inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303) Etoposide Phase 3 Not yet recruiting GlaxoSmithKline Nov 18, 2026 Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer Etoposide Not applicable Not yet recruiting LI FENG Nov 10, 2026 Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia Etoposide Phase 2 Enrolling by invitation Guangdong Second Provincial General Hospital Nov 6, 2026 Allogeneic Cell Therapy in Refractory T-Cell Lymphoma Etoposide Phase 2 Not yet recruiting University Medical Center Goettingen Nov 5, 2026 A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression-Free Survival in Limited-Stage Small Cell Lung Cancer Etoposide Phase 2 / Phase 3 Not yet recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Nov 5, 2026 Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma Etoposide Phase 2 Not yet recruiting St. Jude Children's Research Hospital Nov 4, 2026 Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer Etoposide Phase 2 Not yet recruiting Tianjin Medical University Cancer Institute and Hospital Nov 2, 2026 A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated Teniposide Not applicable Not yet recruiting Sun Yat-sen University Oct 26, 2026 Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer Etoposide Early phase 1 Recruiting Oliver Jonas Oct 23, 2026 The CARDIOPROTECT Trial Dexrazoxane Phase 2 Not yet recruiting Beth Israel Deaconess Medical Center Jun 17, 2026 Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study Teniposide Phase 2 Recruiting Sun Yat-sen University May 13, 2026 Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. Teniposide Phase 2 Recruiting Chengcheng Guo Sep 23, 2025 Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL Teniposide Phase 2 / Phase 3 Recruiting Huashan Hospital Sep 22, 2025 Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma Dexrazoxane Phase 2 Recruiting University of Colorado, Denver Aug 15, 2025 Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL Teniposide Not applicable Recruiting The First Affiliated Hospital of Soochow University Jul 20, 2025 Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer Teniposide Phase 2 Recruiting Shanghai Pulmonary Hospital, Shanghai, China Jan 6, 2025 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. Amsacrine Phase 3 Recruiting Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Dec 3, 2024 Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Teniposide Phase 2 Not yet recruiting Peking University Shenzhen Hospital Nov 18, 2024 Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Dexrazoxane Phase 3 Recruiting Children's Oncology Group Oct 18, 2024 CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients Dexrazoxane Phase 2 Recruiting Princess Maxima Center for Pediatric Oncology Feb 16, 2024 Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma Dexrazoxane Phase 3 Recruiting Stichting Hemato-Oncologie voor Volwassenen Nederland Jan 23, 2024 Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML Amsacrine Phase 1 / Phase 2 Recruiting Heinrich-Heine University, Duesseldorf Apr 11, 2023 Venetoclax Basket Trial for High Risk Hematologic Malignancies Dexrazoxane Phase 1 Active, not recruiting Andrew E. Place, MD Mar 23, 2022 A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Berubicin Phase 2 Active, not recruiting CNS Pharmaceuticals, Inc. Feb 21, 2021 A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Dexrazoxane Phase 3 Recruiting Shanghai Children's Medical Center Jul 20, 2020 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Dexrazoxane Phase 3 Recruiting Children's Oncology Group Mar 3, 2020 Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR Vosaroxin Phase 2 / Phase 3 Recruiting University Hospital, Angers Apr 15, 2015
Show all 27Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094255 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets